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Abstract: The aim of this work was to study the effects of dehydroepiandrosterone (DHEA) and metformin (M) on nitric 
oxide (NO) system and oxidative stress in embryo implantation sites of early pregnant mice. The biguanide M is used for 
treating polycystic ovary syndrome but its complete mechanism of action remains unknown. Nitric oxide (NO) has impor-
tant protective roles during pregnancy, keeping uterine relaxation and vascular function. However, its overproduction 
leads to nitrative stress by producing reactive nitrogen species. Here we measured NO content by Griess method and the 
localization of inducible and endothelial nitric oxide synthase (iNOS and eNOS) by immunohistochemistry in implanta-
tion sites. Also we measured lipid peroxidation by TBA-RS, glutathion by Ellman’s reaction and antioxidant enzymes by 
enzymatic kinetics in uterine homogenates. We found that the expression of both iNOS and eNOS and the NO content 
were increased with DHEA (p<0.001 for all) and restored to control levels with DHEA+M. Oxidative stress: DHEA in-
creased lipid peroxidation (p<0.01) and glutathione (GSH, p<0.01). With DHEA+M lipid peroxidation was restored to 
control levels. The activities of the antioxidant enzymes superoxide dismutase and catalase were not modified. We con-
clude that hyperandrogenization with DHEA enhances the NO system and lipid peroxidation in implantation sites of early 
pregnant mice and that M treatment prevents these effects. 
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INTRODUCTION 
Nitric oxide (NO) is an essential metabolite involved in 
vascular function and in numerous physiological processes 
that maintain homeostasis in mammals. It is a vasodilator 
agent and it has a biological role to modulate local blood 
flow and platelet function [1-4]. The production of NO is 
due to three isoforms of the NO synthase. In healthy vessels 
endothelial NOS (eNOS) and neuronal NOS (nNOS) consti-
tutively expressed, Ca-dependent enzymes. On the other 
hand, when the vascular system is diseased and defense 
mechanisms are activated, the mediators of inflammation 
induce a NO synthase non-responsive to calcium (iNOS) 
which produces large quantities of NO in most of the cells of 
the vessel wall [4-6]. An inadequate production of NO could 
play a role in many vascular diseases such as hypertension, 
atherosclerosis, or vascular hyporeactivity associated with 
septicaemic shock [1].  
In pregnancy, NO plays important roles in implantation, 
decidualization, vasodilatation of decidual, placental and 
uterine vessels and myometrial relaxation [7]. It has been  
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reported that NO participates in vascular invasion by the 
trophoblast, and it may play a role in maintaining uterine 
quiescence during pregnancy [8-11]. However, an overpro-
duction of NO can lead to the increase of reactive nitric ox-
ide species (RNOS, more aggressive oxidant species than 
reactive oxygen species: ROS) [12]. NO could have a dual 
action (protective or pro-oxidant) in the corpus luteum de-
velopment [13, 14]. Peroxynitrite (ONOO-/ONOOH), the 
product of the reaction of NO with superoxide (O2-), leads to 
nitrative stress, a pro-oxidant and to a pro-inflammatory 
status, which is associated to pregnancies complicated by 
preeclampsia, intrauterine growth restriction, pregestational 
diabetes and miscarriage [13-17]. Besides, it was found that 
eNOS gene influences the risk of pre-eclampsia and the re-
currence of negative pregnancy events [18]. 
Although NO synthases iNOS and eNOS have been iden-
tified in rodent uterus via western blot analysis and immuno-
histochemistry during implantation and late gestation [19, 
20], very few localization and/ or quantification studies of 
NOS and NO during early pregnancy have been performed. 
Dehydroepiandrosterone (DHEA) is the most abundant 
androgen found in women with polycystic ovary syndrome 
(PCOS) [21]. This hormone is involved in immune homeo-
stasis and is increased in normal pregnancy contributing to 
the development of gestation [22]. It has been reported that 
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DHEA regulates vascular function, having a protective role 
[23]. However, abnormally increased DHEA leads to an im-
balance in ovarian function and in detrimental effects on 
endometrial function. This results in low implantation rates 
and miscarriage [24-27]. Simoncini et al. 2003 have reported 
that DHEA induces NO synthesis by a direct effect on eNOS 
[28]. We have previously developed a murine model hyper-
androgenized with DHEA which reflects endocrine and im-
mune aspects of women with PCOS during early pregnancy 
[26]. 
The insulin-sensitizing drug metformin (M) is widely 
used in the treatment of type II diabetes mellitus [29, 30] and 
PCOS [31, 32]. These conditions are accomplished with a 
decreased antioxidant capacity that could contribute to the 
known increased risk of cardiovascular diseases as athero-
sclerosis or hypertension in patients with diabetes and PCOS 
[33, 34]. The biguanide M is a non-hormonal treatment that 
has shown to reduce oxidative stress in numerous systems. 
Apparently it exerts its antioxidant effects directly scaveng-
ing ROS or indirectly modulating the intracellular ROS pro-
duction [35-40]. Moreover, NO has been proposed as an 
intermediate of the M action [41]. In women with PCOS, it 
has been seen that M treatment decreases androgen levels, 
improves frequency of menstrual cycle and ovulation [42-
46] and prevents abortions in early pregnant women with 
PCOS [47-50]. Considering that there are an increasing 
number of women with PCOS who became pregnant after M 
treatment it is expected that the use of this drug around and 
during the time of pregnancy will increase. However, the 
clinical practice is ahead of the knowledge of the mechanism 
involved, which remains partially unknown. 
In recent works using our DHEA-treated-early pregnancy 
model we have shown that M prevented some endocrine and 
immune alterations induced by DHEA: embryo resorption, 
glucose, progesterone, progesterone-induced blocking factor 
(PIBF) and cyclooxygenase2 (COX2) in the implantation 
sites, cytokine production, ovarian oxidative stress and uter-
ine NOS activity [51, 52]. 
In the present report we focused on determining the lo-
calization of iNOS and eNOS, as well as the NO production 
and oxidative stress at the implantation sites during early 
pregnancy. We also were interested in knowing the local 
effects of DHEA and M on these parameters. In this way, we 
are expanding our previous findings on the mechanisms by 
which DHEA induces and M prevents embryo resorption on 
early pregnant BALB/c mice. 
MATERIALS AND METHODS 
Animals 
All procedures involving animals were conducted in ac-
cordance with the Guide for the Care and Use of Laboratory 
Animals (The National Academies Press, Washington, D.C., 
2011 [53]). The studies were approved by the Independent 
Committee on Ethics in Research of the School of Medicine 
of the University of Buenos Aires. The mice were housed 
under controlled temperature (22 º C) and illumination (14 h-
light, 10-h darkness; lights on at 05:00) and allowed free 
access to Purina Rat Chow and water. A total of 86 virgin 
female BALB/c mice (8-12-week-old) were paired with 
BALB/c males (8-12-week-old). The animal model used has 
been previously described [52]. Briefly, the day of appear-
ance of a coital plug was taken as day 0 of pregnancy. Im-
plantation occurs in the morning of the 5th day, therefore, on 
6th and 7th days (post-implantation) animals were divided in 
4 groups: Control (supplied with vehicles), M (treated orally 
by canulla with 240 mg/kg of metformin in 0.1 ml of water), 
DHEA (injected s.c. with 60 mg/kg of dehydroepiandroster-
one in 0.1 ml of sesame oil) and DHEA+M (treated under 
the same conditions with DHEA and M). On day 8 of preg-
nancy (bodyweight 20 ± 2 g), animals were euthanized by 
cervical dislocation. After embryos were removed, uterine 
tissues from 14 animals per group were divided as follows: 7 
uteri of each group were immediately homogenized in buffer 
Tris-Base 20 mM, pH=7, 6 to determine oxidant-antioxidant 
parameters (superoxide dismutase and catalase activity, lipid 
peroxidation, glutathione and nitrites concentration). The 
remaining 7 uteri were immediately fixed in 4 % (w/v) para-
formaldehyde to carry out immunohistochemical determina-
tion of eNOS and iNOS. 
In order to test any long-term adverse effect of the treat-
ments, 3 additional groups of mice (10 animals each) includ-
ing Control, M and DHEA+M, were allowed to proceed to 
parturition. These animals had a normal pregnancy with 
normal number and morphology of pups (8- 12 pups/litter). 
Experimental Procedures 
Immunohistochemical Localization of iNOS and eNOS 
The immunolocalization of iNOS and eNOS was per-
formed on implantation sites. Uterine sections were stained 
with immunoperoxidase staining kit CSA/ HRP (Dako). 
Briefly, uterine tissues fixed in 4% paraformaldehyde were 
embedded in paraffin wax, consecutively cut (6-µm-thick 
sections) and placed on silanized glass slides (Biobond; Brit-
ish Biocell International, Cardiff). Only sections that passed 
through the center of the implantation sites were selected.  
Then, tissue sections were deparaffinized, rehydrated 
through a series of graded alcohols and washed in PBS. En-
dogenous peroxidase activity was blocked with 0.1 % (v/v) 
hydrogen peroxide for 50 min. Non-specific binding sites 
were blocked by treating tissues with TNB blocking reagent 
(NEN Life Science Products, Boston, MA, USA). Then, sec-
tions were incubated overnight at 4º C with rabbit polyclonal 
anti- human eNOS and iNOS antibodies respectively (Cay-
man Chemical Company, Ann Arbor, MI, USA) diluted 
1:200 in blocking buffer. Control sections were processed 
without primary antibody. Sections were then incubated for 
30 min with biotinylated anti-rabbit antibody, washed in 
PBS and treated with streptavidin–biotin complex for 30 
min. The reaction was visualized by diaminobenzidine (DAB 
staining kit, Dako; Hamburg, Germany) and sections were 
counterstained with haematoxylin and covered with DPX 
(Sigma-Aldrich, St Louis, MO, USA). 
Immune mark was analyzed using Image-Pro Plus ver-
sion 4.1 (Media Cybernetics, Silver Spring, MD). It was de-
termined marked area/ total area and expressed as a percent-
age. 
Nitric Oxide Concentration 
Nitrites concentration was determined by the Griess reac-
tion, a colorimetric assay based on the reaction of NaNO2 
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with sulfanilic acid that produces color readable at 540 nm 
[54]. Samples were incubated with sulfanilic acid and values 
were referred to a NaNO2 standard curve. NO2 concentration 
was expressed as nmol NO2/mg protein. 
Oxidative Stress-Related Parameters 
Uterine tissues without embryos were homogenized in 
buffer Tris-Base 20 mM, pH=7,6 with a Teflon-glass ho-
mogenizer on ice. The suspension was centrifuged at 9000 
×g for 10 min at 4°C. The pellet was discarded and the su-
pernatant was saved and stored at –20º C for the oxidative 
stress determinations that are described ahead and for the 
protein content determination by Bradford method. 
Superoxide Dismutase (SOD) 
SODs are a group of metalloenzymes that detoxify ROS 
through the conversion of O2•- to hydrogen peroxide and 
molecular oxygen. Total SOD activity was assayed by a 
spectrophotometric method based on the inhibition of a su-
peroxide-induced epinephrine oxidation [55]. Briefly, 30 
mM epinephrine in 0.05% v/v acetic acid was added to 50 
mM glycine buffer (pH = 10,2) with uterine homogenates. 
SOD activity was measured at 480 nm for 4 min. One unit 
(U) is equivalent to the amount of enzyme that inhibited the 
oxidation of epinephrine by 50%. It was expressed as 
USOD/ mg protein. 
Catalase 
The enzyme catalase promotes the conversion of hydro-
gen peroxide (H2O2) into water and oxygen (H2O + O2). The 
consumption of H2O2 was monitored by spectrophotometer 
in a reaction medium consisting of 50 mM phosphate buffer, 
pH 7,2 and 3 mM H2O2 every 10 sec during 1 min at 240 nm 
[56]. Results were expressed as nmol catalase/ mg protein. 
Lipid Peroxidation 
The amount of malondialdehyde (MDA), product of the 
breakdown of polyunsaturated fatty acids, may be taken as 
an index of peroxidation reaction. The TBA reactive species 
(TBA-RS) method was previously described [57] and quanti-
fies MDA, that reacts with trichloroacetic acid (TCA) 15% 
(w/v)- thiobarbituric acid (TBA) 0.375% (w/v)- HCI 0.25M, 
yielding a red compound that absorbs at 535 nm. Homogen-
ates were treated with TCA-TBA-HCl and heated for 15 min 
in water at 100°C. After cooling, the flocculent precipitate 
was removed by centrifugation at 1000 ×g for 10 min. The 
absorbance of samples was determined at 535 nm. Results 
were expressed as nmol MDA/ mg protein. 
Glutathione Content 
The GSH assay was previously described [58]. The re-
duced form of GSH comprises the bulk of cellular protein 
sulphydryl groups. Thus, measurement of acid-soluble thiol 
is used for estimation of GSH content in tissue extracts. 
Briefly, 300 µl of uterine homogenates were incubated with 
buffer Tris 1.75 M (pH= 7, 4) containing NADPH and GSH 
reductase. The reaction involves the enzymatic reduction of 
the oxidized form (GSSG) to GSH. When Ellman’s reagent 
(a sulphydryl reagent 5, 5-dithiobis-2 nitrobenzoic acid; 
Sigma-Aldrich, St Louis, MO, USA) is added to the incuba-
tion medium, the chromophoric reaction product absorbs at 
412 nm with a linear increase during 6 min; after this, the 
reaction remains constant. Results were expressed as mmol 
GSH/mg protein. 
Statistical Analysis 
Statistical analyses were carried out using the Instat pro-
gram (GraphPAD software, San Diego, CA, USA). One way 
ANOVA test was used (Tukey post-test Multiple Compari-
son that compares all the pairs of columns). A P value < 0.05 
was considered significant. Results are presented as mean ± 
SEM. 
RESULTS 
Expression of iNOS and eNOS in Implantation Sites 
The immunohistochemical analysis of iNOS and eNOS 
in implantation sites showed that in Control and DHEA+M 
these enzymes are expressed in trophoblastic and maternal 
blood cells (Fig. 1A and C for iNOS, 2A and C, for eNOS: 
tr, bc). The expression in M treated mice showed an appear-
ance similar to Control (picture not shown). In DHEA 
treated mice these proteins showed an increased expression 
on decidual matrix when compared to Control (Fig. 1B and 
2B: md and amd). Quantification of marked area/ total area 
by Image Pro Plus revealed that DHEA increased the protein 
expression of iNOS (Fig. 1D, One way ANOVA *** 
p<0.001) and eNOS (Fig. 2D, One way ANOVA *** 
p<0.001). Treatment with metformin (DHEA+M) partially 
avoided this increase for iNOS while eNOS expression was 
significantly lower than Control (Fig. 2D, One way ANOVA 
*** p<0.001). 
Nitric Oxide Concentration 
Nitric oxide (NO) concentration in uterine homogenates 
without embryos was increased by DHEA respect to Control 
(Fig. 3, One way ANOVA *** p<0.001). This increase was 
avoided by the treatment with metformin (DHEA+M). 
Oxidant/ Antioxidant Status 
Four parameters of the oxidant/ antioxidant status were 
measured in uterine homogenates without embryos: superox-
ide dismutase and catalase, lipid peroxidation and glu-
tathione. Superoxide dismutase and catalase showed no dif-
ferences between treatments (Fig. 4A and Fig. 4B respec-
tively, One way ANOVA p>0.05). Lipid peroxidation suf-
fered an increase in hyperandrogenized mice (DHEA) re-
spect to Control (Fig. 4C, One way ANOVA ** p<0.01) and 
metformin treatment prevented this effect (DHEA+M). The 
antioxidant metabolite glutathione was increased both with 
DHEA and with DHEA+M (Fig. 4D, One way ANOVA ** 
p<0.01). 
DISCUSSION 
DHEA- Hyperandrogenization 
The present murine model resembles the endocrine and 
immune profile of early pregnant women with PCOS treated 
with metformin [51, 52]. High concentrations of DHEA in-
duce a pro-inflammatory environment and triggers the syn-
thesis of nitric oxide (NO) [52,59,60]. Besides, this induces 
the loss of luteal function and embryo resorption [26,51,61]. 
The present findings show the increase in NOS expression  
and in NO production after hyperandrogenization. We propose 
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Fig. (1). immunolocalization for iNOS in implantation sites from 8 days pregnant mice. Immunohistochemistry was performed in uterine 
sections incubated with anti-iNOS antibody and stained with an immunoperoxidase staining kit. The intense brown color indicates positive 
staining. A: Control (40 X). iNOS immunoreactivity is present in trophoblastic (see tr) and in maternal blood cells (see bc). B: DHEA (40 X). 
The positive staining is extended to the entire decidual matrix (see md and amd). In this slide it is possible to see a remaining trophoblastic 
tissue that is also positive for iNOS. C: DHEA+M (40 X). The localization of iNOS is similar to Control, but the decidual matrix shows a 
more intense staining than this group. D: Quantification of marked area / total area by Image Pro Plus. iNOS expression was increased in 
DHEA treated mice. M treatment partially prevented this effect. Error bars represent the mean +SEM, one way ANOVA *** p<0.001, N=7/ 
group. 
e: embryo. tr: trophoblast. md: mesometrial decidua. amd: antimesometrial decidua. bc: maternal blood cells. 
 
  
A      B 
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Fig. (2). immunolocalization for eNOS in implantation sites from 8 days pregnant mice. Immunohistochemistry was performed in uterine 
sections incubated with anti-eNOS antibody and stained with an immunoperoxidase staining kit. The intense brown color indicates positive 
staining. A: Control (40 X). eNOS immunoreactivity is present in the trophoblastic (see tr) and in maternal blood cells (see bc). B: DHEA 
(40 X). The positive staining is extended to the entire decidual matrix (see md and amd). In this slide it is possible to see a remaining 
trophoblastic tissue that is also positive for eNOS. C: DHEA+M (40 X). The localization of eNOS is similar to Control. D: Quantification of 
marked area / total area by Image Pro Plus. eNOS expression was increased in DHEA treated mice. eNOS expression in DHEA+M was 
significantly lower than in Control. Error bars represent the mean +SEM, one way ANOVA *** p<0.001, N=7/ group. 
e: embryo. tr: trophoblast. md: mesometrial decidua. amd: antimesometrial decidua. bc: maternal blood cells. 
 
Fig. (3). Nitrites concentration was determined by the colorimetric Griess method in uterine homogenates without embryos from 8 days 
pregnant mice. The hyperandrogenized group (DHEA) showed a significant increase in nitrites respect to Control that was avoided by the 
simultaneous treatment with metformin (DHEA+M). Error bars represent the mean+ SEM, one way ANOVA *** p<0.001, N=7/ group. 
  
A      B 
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Fig. (4). oxidative stress in uterine homogenates without embryos from 8 days pregnant mice.  
A: the concentration of the antioxidant enzyme superoxide dismutase (SOD) was determined by a colorimetric method that measures 
epinochrome disappearance. This enzyme showed no differences between treatments. Error bars represent the mean+ SEM, one way ANOVA 
p>0.05, N=7/ group. 
B: the concentration of the antioxidant enzyme catalase was determined by a colorimetric method that measures epinephrine disappearance. 
This enzyme showed no differences between treatments. Error bars represent the mean+ SEM, one way ANOVA p>0.05, N=7/ group. 
C: the product of lipid peroxidation malondialdehyde (MDA) was detected by TBA-RS. Hyperandrogenized mice (DHEA) suffered an 
increase in lipid peroxidation respect to Control and M treatment prevented this effect (DHEA+M). Error bars represent the mean+SEM, one 
way ANOVA ** p<0.01, N=7/ group.  
D: the concentration of the antioxidant metabolite GSH was measured by a colorimetric method that detects the GSH reductase activity. 
Hyperandrogenization increased GSH. The treatment with metformin (DHEA+M) showed no differences with DHEA and was different from 
Control. Error bars represent the mean+SEM, one way ANOVA ** p<0.01, N=7/ group. 
 
that NO has an important role in the cascade of events trig-
gered by high concentrations of DHEA that leads to embryo 
resorption. We base this idea on the increased levels of NO, 
iNOS and eNOS in DHEA-hyperandrogenized mice, with an 
increased rate of embryo resorption and on previous reports 
showing a direct effect of DHEA on NO production modu-
lating iNOS and eNOS expression [28, 51]. In a previous 
work of our group using the same mouse model of hyperan-
drogenization with DHEA, we have observed a decrease in 
NOS activity [51]. The increase in the expression and the 
decrease in the activity of NOS seem contradictory; never-
theless, a possible explanation could be that NOS is in-
creased by high levels of DHEA leading to an overproduc-
tion of NO that could down-regulate the activity of NOS. 
This mechanism of regulation of NO has been seen in other 
experimental models [62, 63].  
The increased concentrations of NO are accomplished by 
oxidative stress in the uterine tissue. This is reflected in the 
increase in lipid peroxidation, index of the oxidative damage 
to the tissue. Regarding the antioxidant defenses, the en-
zymes measured here are not modified by any of the treat-
ments but the antioxidant metabolite GSH is increased by 
DHEA treatment, possibly as a reaction to the oxidation. The 
association between elevated NO and oxidative stress agrees 
with the previous knowledge about the pro-oxidant effect of 
high levels of NO in corpus luteum development [13, 16-18]. 
In this study we localized for the first time the enzymes 
iNOS and eNOS in murine implantation sites during early 
pregnancy: these enzymes are expressed in the trophoblastic 
and maternal blood cells. This localization could be ex-
plained because of the very dynamic remodeling of maternal 
vessels in implantation sites during early pregnancy [8-11]. 
Treatment with Metformin 
In previous reports we have seen that the treatment with 
metformin prevents most of the effects induced by DHEA in 
mice having protective effects on ovaries and uterus. [51, 52, 
64]. In the present work we demonstrate that M totally pre-
vents the increase in NO induced by DHEA. This prevention 
is not due to an effect on the NOS activity (as we have seen 
in a previous work [51]), but to an effect on the NOS expres-
sion. Regarding the expression of iNOS, this treatment re-
verts partially the increase induced by DHEA, whereas with 
regard to the eNOS M reverts its increase and even we ob-
serve a decrease in DHEA+M respect to Control that we 
cannot explain. 
M is known to have an antioxidant role [35-40]. Our pre-
sent results are in agreement with this because M prevents 
the increase in lipid peroxidation induced by DHEA. GSH is 
also elevated in DHEA+M. The increase in GSH could have 
a role in the prevention of lipid peroxidation because it is an 
instantaneous antioxidant defense. 
The treatment with metformin seems to be a good option 
for maintaining pregnancy to term in patients with PCOS. 
Regulation of nitric oxide by M probably favors the normal 
vascular function in these patients. It could contribute to de-
creasing the risk of cardiovascular diseases [33, 34]. Besides, 
M is a non-hormonal treatment and did not show to be tera-
togenic, making it a good choice for patients with PCOS [50, 
64]. 
20     The Open Reproductive Science Journal, 2013, Volume 5 Luchetti et al. 
There remain some aspects to be studied, including long 
time effects of this treatment in pregnancy. It would be inter-
esting to focus on the offspring born under metformin treat-
ment, its glucose metabolism, its endocrine regulation and 
reproductive performance. 
CONCLUSION 
On the basis of the present results, we conclude that 
DHEA induces and metformin prevents a detrimental in-
crease in NOS and NO and lipid peroxidation in implanta-
tion sites during early pregnancy in mice. This work contrib-
utes to the knowledge and explanation of the etiology of 
PCOS during early pregnancy. It investigates the mechanism 
of action of DHEA, one of the principal androgens present in 
PCOS, and of metformin, a promising drug for treatment of 
PCOS. Moreover, this study deepens the knowledge of some 
important factors that are decisive for pregnancy, like NOS-
NO system and oxidant/antioxidant balance. These factors 
contribute to pregnancy success or fail and lead to miscar-
riage. 
ABBREVIATIONS 
COX2 = cyclooxygenase 2 
DHEA = dehydroepiandrosterone 
eNOS = endothelial nitric oxide synthase 
g = times gravity 
GSH = Glutathione 
h = hours 
HCI = hydrochloric acid 
iNOS = inducible nitric oxide synthase 
Kg = kilograms 
M = metformin 
MDA = malondialdehyde 
mg = milligrams 
min = minutes 
µl = microliters 
mM = millimolar 
NADPH = Nicotinamide adenine dinucleotide phos-
phate 
nm = nanometers 
NO = Nitric oxide 
PCOS = polycystic ovary syndrome 
PIBF = progesterone-induced blocking factor 
pmol = picomoles 
RNOS = reactive nitric oxide species 
ROS = reactive oxygen species 
sc = subcutaneously 
sec = seconds 
SOD = Superoxide dismutase 
TBA = thiobarbituric acid 
TCA = trichloroacetic acid 
w/v = weight/volume 
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